Gabriella Gobbi, MD, PhD
Dr. Gabriella Gobbi鈥痠s a Professor in the Department of Psychiatry, 不良研究所.听
Dr. Gobbi leads a laboratory of basic science (Neurobiological Psychiatry Unit), holds the Canadian Research Chair in Therapeutics for Mental Health, and works as a Staff Psychiatrist at the Mood Disorder Clinic of the 不良研究所 Health Center. Her research approach spans from bench to bedside, bridging the gaps between fundamental and clinical research.听
Dr. Gobbi received her MD (1991) and her specialty in Psychiatry and Psychotherapy (1995) from the Catholic University of Rome (Italy). She also earned a PhD in Neuroscience at the University of Cagliari (Italy) and finalized a post-doc at 不良研究所 (Montreal, Canada) in 2001.听
Dr Gobbi鈥檚 lab is interested in understanding the pathophysiology of mental diseases and discover new treatments and cures for them. Her laboratory is studying the short- and long-term effects of cannabis use in mood and anxiety, and the potential beneficial effects of the drugs acting on the endocannabinoid system (endogenous cannabis) in the cure of mental diseases. Her lab also discovered and patented novel selective agonists of the melatonin MT1 and MT2 receptors for pain, insomnia, and anxiety. More recently, she published and patented research unveiling the mechanism of action of LSD and psychedelics in social anxiety and post-stress anxiety.听
Dr. Gobbi is the author of more than 140 highly cited manuscripts in high impact journals, 20 book chapters, one book, and inventor of international patents in psychopharmacology. Her research is highly financed by governmental agencies (CIHR, FRQS, MEI, CQDM) and the private sector. In recognition of her achievements, she was awarded with many prizes, including the Venezia Prize in 2015, the Samarthji Lal prize in 2017 from the Boeckh Foundation, the 不良研究所 Principal鈥檚 Prize for Media Engagement in 2019, the Brain Research Award from the CINP (International College of Neuropsychopharmacology) in 2022 and the Award for Innovations in Psychopharmacology from the CCNP (Canadian College of Neuropsychopharmacology) in 2022. She is a Fellow of the American College of Neuropsychopharmacology and elected President of the CINP.听
A trilingual speaker, she has been invited to speak at conferences around the world and has served as reviewer/editor for many journals and international grant agencies in Europe and the USA. Dr Gobbi served as an expert witness for the Canadian Senate (2012), the Ministry of Health (2019) and the Ministry of Justice (2021) of Quebec for the cannabis legislation. Her studies on cannabis have influenced policies raising the age of cannabis consumption from 18 to 21 years in Quebec and banning the advertisement of cannabis.听
Gobbi, G., Atkin, T., Zytynski, T., Wang, S., Askari, S., Boruff, J., ... & Mayo, N. (2019). Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood: a systematic review and meta-analysis. JAMA psychiatry, 76(4), 426-434.听
De Gregorio, D., Popic, J., Enns, J. P., Inserra, A., Skalecka, A., Markopoulos, A., ... & Gobbi, G. (2021). Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission. Proceedings of the National Academy of Sciences, 118(5), e2020705118.听
De Gregorio, D., McLaughlin, R. J., Posa, L., Ochoa-Sanchez, R., Enns, J., Lopez-Canul, M., ... & Gobbi, G. (2019). Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. Pain, 160(1), 136-150.听
Comai, S., & Gobbi, G. (2014). CCNP Award Paper: Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: a novel target in psychopharmacology. Journal of Psychiatry and Neuroscience, 39(1), 6-21.听
